Keros Therapeutics (KROS) Revenue (2019 - 2025)

Keros Therapeutics (KROS) has reported Revenue for 6 consecutive years, with $385000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Revenue fell 87.34% year-over-year to $385000.0; the trailing twelve-month figure through Jun 2026 stood at $32.8 million (down 85.91% YoY), and the FY2025 full-year result was $244.1 million, up 6774.96% from the prior year.
• Revenue eased to $385000.0 in Q4 2025 per KROS's latest filing, from $14.3 million in the prior quarter.
• Across five years, Revenue topped out at $211.2 million in Q1 2025 and bottomed at $8000.0 in Q3 2023.
• Historically, Revenue has averaged $22.0 million across 5 years, with a median of $388000.0 in 2024.
• The widest YoY moves for Revenue: up 254413.25% in 2025, down 87.34% in 2025.
• Over 5 years, Revenue stood at $20.0 million in 2021, then retreated by 10.0% to $18.0 million in 2022, then plunged by 99.21% to $143000.0 in 2023, then soared by 2027.27% to $3.0 million in 2024, then plunged by 87.34% to $385000.0 in 2025.
• According to Business Quant data, Revenue over the past three periods registered $385000.0, $14.3 million, and $18.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.